| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3464 | 2016 |
| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2622 | 2017 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 2177 | 2017 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1462 | 2017 |
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution EC De Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ... Science 346 (6206), 251-256, 2014 | 1368 | 2014 |
| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 940 | 2019 |
| Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ... Cell 173 (3), 581-594. e12, 2018 | 892 | 2018 |
| Lung adenocarcinoma promotion by air pollutants W Hill, EL Lim, CE Weeden, C Lee, M Augustine, K Chen, FC Kuan, ... Nature 616 (7955), 159-167, 2023 | 719 | 2023 |
| Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ... Cell 173 (3), 595-610. e11, 2018 | 707 | 2018 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 679 | 2018 |
| Translational implications of tumor heterogeneity M Jamal-Hanjani, SA Quezada, J Larkin, C Swanton Clinical cancer research 21 (6), 1258-1266, 2015 | 672 | 2015 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 502 | 2017 |
| Embracing cancer complexity: Hallmarks of systemic disease C Swanton, E Bernard, C Abbosh, F André, J Auwerx, A Balmain, ... Cell 187 (7), 1589-1616, 2024 | 413 | 2024 |
| Pervasive chromosomal instability and karyotype order in tumour evolution TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ... Nature 587 (7832), 126-132, 2020 | 389 | 2020 |
| Tracking genomic cancer evolution for precision medicine: the lung TRACERx study M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, ... PLoS biology 12 (7), e1001906, 2014 | 363 | 2014 |
| Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA C Abbosh, AM Frankell, T Harrison, J Kisistok, A Garnett, L Johnson, ... Nature 616 (7957), 553-562, 2023 | 328 | 2023 |
| Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death MS Ricci, SH Kim, K Ogi, JP Plastaras, J Ling, W Wang, Z Jin, YY Liu, ... Cancer cell 12 (1), 66-80, 2007 | 321 | 2007 |
| Geospatial immune variability illuminates differential evolution of lung adenocarcinoma K AbdulJabbar, SEA Raza, R Rosenthal, M Jamal-Hanjani, S Veeriah, ... Nature medicine 26 (7), 1054-1062, 2020 | 305 | 2020 |
| Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer M Jamal-Hanjani, GA Wilson, S Horswell, R Mitter, O Sakarya, ... Annals of Oncology 27 (5), 862-867, 2016 | 287 | 2016 |
| The evolution of lung cancer and impact of subclonal selection in TRACERx AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki, S Ward, ... Nature 616 (7957), 525-533, 2023 | 277 | 2023 |
